Clinical Trial

A Study of CSTI-500 in Patients With Prader-Willi Syndrome

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a proof-of-concept, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CSTI-500 in participants with genetically confirmed Prader-Willi Syndrome (PWS) who are 13 to 50 years of age. Participants will receive increasing doses of CSTI-500, and blood levels will be measured to guide individualized dosing.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-16
Trial Details
NCT Number NCT07348601
Lead Sponsor ConSynance Therapeutics
Conditions Prader-Willi Syndrome
Enrollment 12 participants
Start Date 2026-05
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-15